EpiVax Receives 600,000 Dollars Grant To Develop Treatment For Diabetes From National Institutes Of Health

July 10th, 2008 | Category: Diabetes

EpiVax, Inc, a leader in the field of computational immunology, announced that it has received a grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a division of the National Institutes of Health (NIH), to

develop “Epi-13″, a novel therapeutic for the prevention and treatment of Type 1 diabetes, a devastating and chronic autoimmune disease that affects three million Americans.

Original post by Women’s Health / Gynecology News From Medical News Today

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Netvouz
  • DZone
  • ThisNext
  • MisterWong
  • Wists
  • BlinkList
  • Furl
  • IndianPad
  • Netscape
  • Reddit
  • Simpy
  • Spurl
  • StumbleUpon
  • Technorati
Related Articles
  • Poultry Virus As Human Cancer Treatment
  • Diabetes Drug To Be Developed By EpiVax With JDRF Program Funding
  • Grant To Develop tryout For Buruli Ulcer, A Major African Disease
  • NCI Renewal Grant To Develop New Cancer Therapies
  • Grant To Protect Fertility In Females With Cancer, From Infancy To Womanhood

    • No comments yet. Be the first.

    Leave a reply

    You must be logged in to post a comment.